Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CardioSeq: A Prospective, Single-Center, Open-label Study to Evaluate the Impact of Whole Genome Sequencing (WGS) in Individuals With Cardiovascular Disease

NCT05656183 is registered in ClinicalTrials.gov with Illumina, Inc. as lead sponsor.

NCT NCT05656183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05656183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CardioSeq: A Prospective, Single-Center, Open-label Study to Evaluate the Impact of Whole Genome Sequencing (WGS) in Individuals With Cardiovascular Disease
Lead sponsor
Illumina, Inc.
Phase
Not applicable
Overall status
Unknown status
Start date
January 6, 2023
Completion date
June 30, 2025
Enrollment
1,500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular diseases